Effects of trilaciclib prior to chemotherapy ± atezolizumab on T-cell activation in patients with newly diagnosed extensive-stage small cell lung cancer.

Aaron D. Stevens; Davey B. Daniel; Jerome H. Goldschmidt; Paul A. Fields; Barb Banbury; Steven Wolfe; Jarrett Glass; Janet K. Horton; Jessica Sorrentino

doi:10.1200/JCO.2021.39.15_SUPPL.E20582

Effects of trilaciclib prior to chemotherapy ± atezolizumab on T-cell activation in patients with newly diagnosed extensive-stage small cell lung cancer.

Aaron D. Stevens
, Davey B. Daniel
, Jerome H. Goldschmidt
, Paul A. Fields
, Barb Banbury
, Steven Wolfe
, Jarrett Glass
, Janet K. Horton
, Jessica Sorrentino

Research Triangle Park
Sarah Cannon Research Institute
Blue Ridge Cancer Care, Blacksburg, VA;
Adaptive Biotechnologies, Seattle, WA;

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
Volume	39
DOIs	https://doi.org/10.1200/JCO.2021.39.15_SUPPL.E20582
State	Published - May 20 2021
Externally published	Yes

Disciplines

Medicine and Health Sciences
Oncology
Internal Medicine

Access to Document

10.1200/JCO.2021.39.15_SUPPL.E20582License: Unspecified

Cite this

Stevens, A. D., Daniel, D. B., Goldschmidt, J. H., Fields, P. A., Banbury, B., Wolfe, S., Glass, J., Horton, J. K., & Sorrentino, J. (2021). Effects of trilaciclib prior to chemotherapy ± atezolizumab on T-cell activation in patients with newly diagnosed extensive-stage small cell lung cancer. Journal of Clinical Oncology, 39. https://doi.org/10.1200/JCO.2021.39.15_SUPPL.E20582

@article{05f99b44d53b4b1c8b351378f651b45c,

title = "Effects of trilaciclib prior to chemotherapy ± atezolizumab on T-cell activation in patients with newly diagnosed extensive-stage small cell lung cancer.",

author = "Stevens, \{Aaron D.\} and Daniel, \{Davey B.\} and Goldschmidt, \{Jerome H.\} and Fields, \{Paul A.\} and Barb Banbury and Steven Wolfe and Jarrett Glass and Horton, \{Janet K.\} and Jessica Sorrentino",

note = "e20582 Background: Chemotherapy ± immunotherapy has demonstrated meaningful clinical benefit to patients (pts) with extensive-stage small cell lung cancer (ES-SCLC); however, chemotherapy-induced damage to the immune system can potentially diminish treatment efficacy. Trilaciclib (T) is an intravenous cyclin-dependent kinase 4/6 inhibitor that protects hematopoietic stem and progenitor cells from chemotherapy-induced damage (myeloprotection) and may directly enhance antitumor immunity.",

year = "2021",

month = may,

day = "20",

doi = "10.1200/JCO.2021.39.15\_SUPPL.E20582",

language = "American English",

volume = "39",

journal = "Journal of Clinical Oncology",

}

TY - JOUR

T1 - Effects of trilaciclib prior to chemotherapy ± atezolizumab on T-cell activation in patients with newly diagnosed extensive-stage small cell lung cancer.

AU - Stevens, Aaron D.

AU - Daniel, Davey B.

AU - Goldschmidt, Jerome H.

AU - Fields, Paul A.

AU - Banbury, Barb

AU - Wolfe, Steven

AU - Glass, Jarrett

AU - Horton, Janet K.

AU - Sorrentino, Jessica

N1 - e20582 Background: Chemotherapy ± immunotherapy has demonstrated meaningful clinical benefit to patients (pts) with extensive-stage small cell lung cancer (ES-SCLC); however, chemotherapy-induced damage to the immune system can potentially diminish treatment efficacy. Trilaciclib (T) is an intravenous cyclin-dependent kinase 4/6 inhibitor that protects hematopoietic stem and progenitor cells from chemotherapy-induced damage (myeloprotection) and may directly enhance antitumor immunity.

PY - 2021/5/20

Y1 - 2021/5/20

UR - http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e20582

U2 - 10.1200/JCO.2021.39.15_SUPPL.E20582

DO - 10.1200/JCO.2021.39.15_SUPPL.E20582

M3 - Article

VL - 39

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

Effects of trilaciclib prior to chemotherapy ± atezolizumab on T-cell activation in patients with newly diagnosed extensive-stage small cell lung cancer.

Disciplines

Access to Document

Other files and links

Cite this